List of Excipients in Branded Drug HEARTBURN RELIEVER 75

Generic Drugs Containing HEARTBURN RELIEVER 75

Company	Ingredient	NDC	Excipient
Discount Drug Mart	ranitidine	53943-740	CELLULOSE, MICROCRYSTALLINE
Discount Drug Mart	ranitidine	53943-740	FD&C RED NO. 40
Discount Drug Mart	ranitidine	53943-740	FERROSOFERRIC OXIDE
Discount Drug Mart	ranitidine	53943-740	HYPROMELLOSE
Discount Drug Mart	ranitidine	53943-740	MAGNESIUM STEARATE
Discount Drug Mart	ranitidine	53943-740	POLYETHYLENE GLYCOL
Discount Drug Mart	ranitidine	53943-740	TITANIUM DIOXIDE

What are the Most Frequently-Used Excipients in HEARTBURN RELIEVER 75?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C RED NO. 40
1	FERROSOFERRIC OXIDE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	TITANIUM DIOXIDE

Heartburn Reliever 75 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 2, 2026

Heartburn Reliever 75 is generally marketed as an over-the-counter nizatidine 75 mg product, an H2-receptor antagonist for relief and prevention of heartburn. Its commercial opportunity is not based on molecule exclusivity. Nizatidine is a mature generic active ingredient with limited patent protection and strong substitution risk. The highest-value opportunities are differentiated excipients, easier administration, package design, combination products, and private-label distribution.

The exact excipient portfolio is manufacturer-specific. Commercial decisions should therefore distinguish between the active ingredient, the dosage form, and the product’s FDA-listed inactive ingredients.

What is Heartburn Reliever 75 and which active ingredient does it contain?

Heartburn Reliever 75 typically contains nizatidine 75 mg per oral unit. Nizatidine reduces gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells. FDA-approved labeling identifies nizatidine as a treatment for active heartburn and for prevention of heartburn associated with food and beverage consumption (FDA, 2024a).

Attribute	Product profile
Active ingredient	Nizatidine
Strength	75 mg
Therapeutic class	H2-receptor antagonist
Route	Oral
Likely dosage forms	Capsule or tablet
Regulatory category	OTC drug product
Primary indication	Heartburn relief and prevention
Principal competitors	Famotidine, calcium carbonate antacids, alginate products, proton-pump inhibitors
Biosimilar exposure	None
Generic substitution risk	High

Nizatidine is a small molecule, not a biologic. Biosimilar regulation does not apply. The relevant competitive threat is generic and private-label substitution under the abbreviated new drug application pathway or other applicable OTC regulatory pathways.

What excipients are used in nizatidine 75 mg products?

Inactive ingredients vary by manufacturer and dosage form. Typical nizatidine oral products may use lactose or another filler, starch, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide, and colorants. A product-specific DailyMed entry is the controlling source for the marketed formulation (National Library of Medicine, 2024).

Functional role of common excipients

Excipient category	Typical function	Commercial relevance
Lactose, microcrystalline cellulose, or starch	Diluent and tablet or capsule bulk	Determines allergen, dietary, and label positioning
Povidone or pregelatinized starch	Binder	Affects compression and mechanical strength
Crospovidone or sodium starch glycolate	Disintegrant	Controls tablet breakup and dissolution
Colloidal silicon dioxide	Glidant	Improves powder flow and content uniformity
Magnesium stearate	Lubricant	Reduces sticking during compression
Gelatin or hypromellose	Capsule shell	Determines animal-origin and vegetarian claims
Titanium dioxide and colorants	Appearance and product identification	Affects clean-label and global-market positioning
Sodium lauryl sulfate	Wetting agent	May improve dissolution but can create tolerability and label concerns
Film-coating polymers	Protection, taste masking, appearance	Supports swallowability and premium positioning

The excipient strategy should begin with the intended product claim. A low-cost store-brand capsule requires a different formulation from a premium, dye-free, lactose-free, easy-swallow tablet.

What excipient strategies can differentiate Heartburn Reliever 75?

The strongest opportunities are practical improvements that consumers can recognize at the point of purchase.

Lactose-free formulation

A lactose-free product can broaden use among consumers avoiding lactose or seeking a simpler inactive-ingredient profile. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or anhydrous dibasic calcium phosphate can replace lactose, subject to compatibility, compression, dissolution, and manufacturing requirements.

A lactose-free claim has value in private-label retail because many competing OTC products use conventional fillers. The claim must be supported by supplier controls and finished-product testing.

Dye-free formulation

A dye-free capsule or tablet reduces formulation complexity and supports a clean-label positioning. It also avoids colorant-specific restrictions in certain foreign markets. The trade-off is reduced visual differentiation, which can be addressed through embossing, package graphics, and unit-dose blister identification.

Gelatin-free dosage form

Replacing gelatin with a hypromellose capsule can support vegetarian and religious-dietary positioning. A tablet may provide a simpler path if the target market does not require capsule presentation.

The principal technical issue is release performance. Capsule-shell composition, moisture transmission, fill density, and storage conditions must be controlled to maintain dissolution and physical stability.

Easy-swallow tablet

Nizatidine 75 mg has a relatively low dose load, creating an opportunity for a small tablet or coated caplet. A smooth film coating can reduce friction and improve consumer acceptance. The formulation should avoid excessive hardness, which can delay disintegration.

A scored tablet may have limited value because the 75 mg unit is intended as a fixed OTC dose. A smaller unit or thinner caplet is more commercially relevant than dose splitting.

Chewable or orally disintegrating product

A chewable or orally disintegrating nizatidine product could address consumers who do not want to swallow capsules. The main formulation barriers are taste, moisture sensitivity, friability, and dose uniformity.

Potential excipient systems include mannitol for mouthfeel, crospovidone for rapid breakup, sucralose or acesulfame potassium for sweetness, and flavor systems for taste masking. Nizatidine’s odor and taste profile must be established through sensory testing before commercialization.

A rapidly dissolving product is not automatically a faster heartburn treatment. The consumer benefit is administration convenience, not necessarily superior pharmacodynamic onset.

Sugar-free formulation

Sugar-free chewables can target diabetic consumers and consumers avoiding sucrose. Polyols such as sorbitol, xylitol, or mannitol may be considered, but gastrointestinal tolerability and laxation warnings require evaluation at the proposed dose and serving size.

Low-moisture formulation

Moisture control is important for products using hygroscopic excipients, chewable matrices, or rapidly disintegrating systems. High-barrier blister packaging, desiccant-containing bottles, and induction seals can protect stability.

The package should be selected with the formulation rather than treated as a separate cost decision. A lower-cost bottle may increase stability risk, caking, capsule-shell changes, or dissolution drift.

What formulations are protected by patents?

The original nizatidine molecule and early product patents are historically old. Commercial protection for a new Heartburn Reliever 75 product would more likely arise from a formulation, manufacturing process, package, or delivery-system patent than from the active ingredient.

Potentially protectable subject matter includes:

• A specific low-moisture nizatidine tablet composition.
• A taste-masked chewable formulation.
• A rapidly disintegrating tablet with defined dissolution performance.
• A dye-free or allergen-reduced capsule-shell system.
• A moisture-barrier package combined with a defined stability profile.
• A co-formulation with an antacid or alginate.
• A manufacturing process that improves content uniformity or reduces degradation products.

A broad claim covering nizatidine with routine pharmaceutical excipients would face substantial validity and obviousness risk. A stronger filing would require a defined composition, measurable performance limits, and comparative data showing an unexpected benefit.

Patent applicants should avoid relying solely on excipient substitution. The most defensible formulation claims generally connect a specific excipient ratio or processing condition to a demonstrated result, such as accelerated stability, dissolution consistency, taste masking, reduced friability, or improved bioavailability.

When does nizatidine lose exclusivity?

Nizatidine’s core small-molecule exclusivity has expired. Prescription and OTC products face mature generic competition, and the active ingredient does not have a current biosimilar or biologic-exclusivity framework.

Exclusivity type	Current commercial significance
Core compound patent	Expired or commercially exhausted
Original prescription exclusivity	Expired
OTC switch exclusivity	Expired
New formulation patent	Possible only for a genuinely differentiated product
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Data exclusivity for a new OTC formulation	Narrow and product-specific

For a new product, the defensible commercial moat is likely to be brand recognition, retail placement, formulation know-how, package design, manufacturing scale, and distribution contracts.

What is the FDA regulatory status of Heartburn Reliever 75?

Nizatidine has an established FDA regulatory history as an H2-receptor antagonist. OTC labeling must comply with applicable FDA requirements for active ingredients, directions, warnings, age restrictions, and claims. The product cannot make unsupported superiority claims over famotidine, antacids, alginates, or proton-pump inhibitors.

The main regulatory workstreams are:

1. Confirming the active ingredient and dosage form.
2. Verifying the applicable OTC monograph or approved application pathway.
3. Establishing inactive-ingredient suitability.
4. Demonstrating finished-product quality and stability.
5. Confirming dissolution and assay performance.
6. Finalizing Drug Facts labeling.
7. Establishing compliant manufacturing and packaging controls.

FDA requirements for OTC labeling and drug manufacturing apply even when the active ingredient is old and widely used (FDA, 2024b; Electronic Code of Federal Regulations, 2024).

What is the Orange Book status of nizatidine products?

The Orange Book identifies approved drug products, patent information, and therapeutic-equivalence evaluations for applicable prescription and certain approved products. A manufacturer should review the specific NDA, ANDA, and listed patent records rather than infer status from the product name alone (FDA, 2024c).

For a new OTC nizatidine product, the key point is that old active-ingredient protection does not normally block market entry. Any remaining barriers would likely involve:

• A listed formulation patent tied to a specific approved product.
• A method-of-use patent with relevant labeling.
• Regulatory exclusivity attached to a particular application.
• Trade-secret manufacturing controls.
• Retail or licensing arrangements.

An OTC formulation with no listed patent and no meaningful exclusivity would have a low legal barrier to generic entry.

Which companies are challenging the nizatidine market?

The competitive field includes generic drug manufacturers, OTC private-label suppliers, pharmacy chains, mass merchants, and branded H2-receptor antagonist companies. Famotidine is the most commercially relevant H2-blocker comparator in the United States. Calcium carbonate, magnesium hydroxide, alginate products, and proton-pump inhibitors compete for the same heartburn consumer but operate through different mechanisms and dosing patterns.

Nizatidine’s commercial disadvantage is lower consumer familiarity than Pepcid, while its potential advantage is a differentiated price, package, or dosage form. Retailers can switch between suppliers when the product is therapeutically substitutable and the formulation has no meaningful consumer loyalty.

What generic entry risks exist for Heartburn Reliever 75?

Generic entry risk is high because the molecule is mature, the dose is conventional, and the dosage form is straightforward. The main risks are commercial rather than patent-based:

• Retailers can replace one supplier with another.
• Consumers may select famotidine or antacid alternatives.
• A low-cost capsule can pressure premium pricing.
• Multiple contract manufacturers can produce comparable products.
• A formulation patent may be designed around easily substituted excipients.
• Product recalls or supply interruptions can shift shelf space rapidly.

A differentiated product can reduce direct price comparison, but it cannot eliminate substitutability. The strongest strategy is a portfolio with a value product, a premium easy-swallow product, and a private-label platform.

How strong is the patent estate for Heartburn Reliever 75?

The patent estate is weak if the product is a conventional nizatidine 75 mg capsule or tablet. The active ingredient is old, and routine excipient combinations are vulnerable to obviousness challenges.

Patent strength improves when claims include:

• Narrow composition ranges supported by stability data.
• A technically difficult manufacturing step.
• A defined impurity-control profile.
• Demonstrated taste-masking performance.
• A package-formulation combination that solves a measurable moisture problem.
• A clinically or commercially meaningful administration benefit.

A portfolio should combine composition claims with process and packaging claims. The objective is to create several independent barriers rather than relying on one broad composition patent.

What licensing deals and manufacturing opportunities exist?

Licensing opportunities are more likely to involve manufacturing and distribution than molecule rights. Potential deal structures include:

Opportunity	Likely counterparty	Commercial rationale
Private-label supply	Pharmacy and mass-retail chains	Volume and shelf access
Formulation license	OTC manufacturer	Faster launch of chewable or ODT product
Capsule-shell license	Specialty excipient supplier	Vegetarian or clean-label differentiation
Packaging license	Blister and barrier-packaging company	Stability and unit-dose positioning
Regional commercialization	Foreign OTC distributor	Geographic expansion
Co-marketing	Established heartburn brand	Consumer trust and channel access

Manufacturing barriers are modest for a standard capsule but higher for taste-masked, orally disintegrating, or moisture-sensitive products. A company with validated coating, granulation, and high-barrier packaging capabilities can obtain a practical advantage even without a broad patent.

How does Heartburn Reliever 75 compare with famotidine products?

Factor	Nizatidine 75 mg	Famotidine products
Consumer recognition	Lower	Higher
Core patent position	Expired	Mature and largely generic
Standard OTC dose	75 mg	Commonly 10 mg or 20 mg
Formulation opportunity	High for differentiation	High but more crowded
Generic risk	High	High
Biosimilar risk	None	None
Brand advantage	Limited unless repositioned	Stronger established brands
Best commercial lever	Price, convenience, clean-label formulation	Brand, strength range, established demand

Nizatidine needs a concrete consumer benefit to compete. A plain generic capsule is unlikely to command a sustained premium.

What generic launch scenarios should investors expect?

The most probable launch scenarios are:

1. A low-cost standard capsule sold through private-label channels.
2. A dye-free and lactose-free product aimed at pharmacy and e-commerce consumers.
3. A chewable or orally disintegrating product with taste-masking technology.
4. A multipack or unit-dose blister product for travel and on-demand use.
5. A combination heartburn product competing with antacid and alginate products.

The first scenario has the lowest technical risk and the weakest margin outlook. The third and fourth scenarios offer better differentiation but require greater formulation, packaging, and consumer-validation investment.

Key Takeaways

• Heartburn Reliever 75 is generally associated with nizatidine 75 mg.
• Nizatidine has no meaningful remaining core-molecule exclusivity.
• Biosimilar risk is irrelevant; generic and private-label substitution risk is high.
• The best excipient opportunities are lactose-free, dye-free, gelatin-free, easy-swallow, chewable, and orally disintegrating formats.
• Formulation patents should claim specific compositions and measurable technical effects.
• Standard capsules have weak patent and commercial defensibility.
• Taste masking, moisture control, and barrier packaging can create stronger practical differentiation.
• Licensing value is concentrated in formulation platforms, manufacturing capability, packaging, and retail distribution.
• A premium product needs a visible consumer benefit to avoid direct price competition with famotidine and antacids.

FAQs

Is nizatidine 75 mg the same as famotidine 20 mg?

No. Both are H2-receptor antagonists, but they are different active ingredients with different labeled strengths, pharmacologic properties, and product histories.

Can a company patent a lactose-free nizatidine formulation?

Possibly, but lactose removal alone is unlikely to support a strong patent. Patentability would improve if the formulation demonstrates a specific technical advantage, such as improved stability, dissolution, taste, or manufacturability.

Is Heartburn Reliever 75 suitable for a pediatric product line?

The existing OTC label, age restrictions, dosing instructions, and safety data control. A pediatric product would require separate regulatory and formulation analysis and should not be created by simply reducing the adult dose.

Does a chewable nizatidine product require new clinical trials?

Not necessarily in every case, but the regulatory pathway depends on the formulation, claims, dosage form, and applicable FDA requirements. Bioequivalence, quality, safety, stability, and labeling requirements may apply.

What is the highest-value commercial feature for a new nizatidine product?

A credible convenience benefit, such as an easy-swallow, taste-masked, unit-dose, or orally disintegrating format, is more defensible than a routine change in filler or lubricant.

References

Electronic Code of Federal Regulations. (2024). 21 C.F.R. parts 210, 211, and 331. https://www.ecfr.gov/

Food and Drug Administration. (2024a). Nizatidine prescribing information and labeling. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/

Food and Drug Administration. (2024b). Over-the-counter drug products and labeling requirements. U.S. Department of Health and Human Services. https://www.fda.gov/drugs

Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

National Library of Medicine. (2024). DailyMed: Nizatidine drug labels. https://dailymed.nlm.nih.gov/dailymed/